You just read:

ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment

News provided by

ViiV Healthcare

16 Aug, 2016, 13:55 BST